Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Summary

Jupiter Neurosciences signed a definitive agreement to acquire exclusive U.S. rights to ALA-002, an FDA-designated Novel Chemical Entity, in a transaction valued at up to $100 million. The deal expands Jupiter's pipeline by adding an experimental CNS drug alongside its Phase II Parkinson's disease program.